10 Sales Behaviors That Prospects Hate
12 Ways to Handle Awkward Business Networking Moments
Uninsured Rate Soars for the Moderately Broke : CDC
Indexed universal life insurance sales climbed to $485 million in the second quarter, up 10% from the total for the second quarter of 2016, according to Wink.
IUL sales were up from $447 million in the first quarter.
(Related: Indexed Universal Life Sales Rise 3.4%: Wink)
Sheryl J. Moore, Wink’s president reported those figures in a summary of results from a survey of life insurance issuers.
Wink, which is based in Des Moines, Iowa, has been collecting IUL sales data for 20 years.
About 81% of the reported IUL sales were to purchasers who said their primary objective was cash accumulation, according to Wink. Other common IUL primary objectives include protecting and maximizing a death benefit and generating retirement income.
Pacific Life Companies reported the highest IUL sales for the second quarter, and it was the market leader in terms of second-quarter IUL sales through banks and through independent agents.
Best Insurance Stocks To Invest In Right Now: Daktronics, Inc.(DAKT)
- [By Monica Gerson]
Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.
- [By Monica Gerson]
Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.
Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.
Best Insurance Stocks To Invest In Right Now: Akebia Therapeutics, Inc.(AKBA)
- [By Todd Campbell]
After inking an expanded deal withOtsuka Pharmaceutical on its midstage anemia drug, shares ofAkebia Therapeutics (NASDAQ:AKBA)skyrocketed 33.4% today.
- [By Lisa Levin]
Shares of Akebia Therapeutics Inc (NASDAQ: AKBA) got a boost, shooting up 39 percent to $13.04. Akebia Therapeutics and Otsuka disclosed that they have expanded relationship with collaboration to develop and commercialize Vadadustat in Europe, China and other territories.
- [By Alex McGuire]
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain
Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%
The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.
- [By WWW.GURUFOCUS.COM]
For the details of Novo A’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Novo+A
These are the top 5 holdings of Novo AInogen Inc (INGN) – 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) – 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) – 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) – 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) – 2,225,000 shares, 4
- [By Keith Speights]
You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin Pharmaceutical (NASDAQ:BMRN), and Idera Pharmaceuticals (NASDAQ:IDRA). These are three biotech stocks that you could be overlooking — but deserve your attention. Here’s why.
Best Insurance Stocks To Invest In Right Now: RXI Pharmaceuticals Corporation(RXII)
- [By Jim Robertson]
Yesterday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotech RXi Pharmaceuticals Corp (NASDAQ: RXII) as a long/bullish trade for our short-term portfolio: